Company profile
Bristol Myers Squibb
Pipeline16 assets
- mezigdomidecereblon E3 ligase / CELMoD; oral targeted protein degrader / Hematologyrelapsed/refractory multiple myelomaPhase IIIactive
- iberdomidecereblon E3 ligase / CELMoD; oral targeted protein degrader / Hematologymultiple myelomaPhase IIIactive
- golcadomidecereblon E3 ligase / CELMoD; oral targeted protein degrader / Hematologyaggressive B-cell lymphomaPhase IIactive
- pumitamigBNT327/BMS-986545 / PD-L1; VEGF-A / bispecific antibody / Oncologysolid tumorsPhase IIIactive
- iza-brenantibody-drug conjugate / Oncologysolid tumorsPhase I/IIactive
- nivolumabOPDIVO / PD-1 / monoclonal antibody / Oncologymultiple oncology indicationsPhase IIIactive LCM
- nivolumab and relatlimab HDPD-1; LAG-3 / antibody combination / Oncologyoncology indicationsPhase IIIactive LCM
- ipilimumabYERVOY / CTLA-4 / monoclonal antibody / Oncologymultiple oncology indicationsPhase IIIactive LCM
- KarXTCOBENFY / muscarinic receptors / small molecule / Neuroscienceneuropsychiatric indicationsPhase IIIactive LCM
- milvexianFactor XIa / small molecule anticoagulant / Cardiovascularthrombotic disordersPhase IIIactive
- BMS-986278BMS-986278 / LPA1 / small molecule antagonist / Fibrosisidiopathic pulmonary fibrosisPhase IIIactive
- BMS-986495BMS-986495 / MTBR tau / antibody / NeuroscienceAlzheimer's diseasePhase IIactive
- imzokitugCCR8 / monoclonal antibody / Oncologysolid tumorsPhase I/IIactive
- obexelimabCD19; FcγRIIb / bifunctional antibody / Immunologyautoimmune diseasesPhase IIIactive
- luspatercept-aamtREBLOZYL / TGF-beta superfamily ligands / recombinant fusion protein / Hematologyanemia indicationsPhase IIIactive LCM
- OncoACP3OncoACP3 / prostate cancer target / radiopharmaceutical therapeutic/diagnostic agent / Oncologyprostate canceractive